Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

News provided by

Aug 12, 2024, 08:00 ET

Management call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET

CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that it will host an investor call on Tuesday, August 13, 2024 at 8:30 am ET to discuss recent and upcoming developments.

Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team. A question and answer period will follow management's discussion.

Conference Call Details:

Date:	Tuesday, August 13, 2024

Time:	8:30 a.m. Eastern Time

Dial In:	1-888-243-4451 (U.S. toll free) 1-412-542-4135 (international)

Webcast:	Register for the webcast here. A replay will be available on the Citius website (www.citiuspharma.com) for 90 days following the event.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.

Investor Contact:

Ilanit Allen
[email protected]
908-967-6677 x113

Media Contact:

STiR-communications
Greg Salsburg
[email protected]

SOURCE Citius Pharmaceuticals, Inc.